Compare ODC & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | AVLN |
|---|---|---|
| Founded | 1941 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | 2026 |
| Metric | ODC | AVLN |
|---|---|---|
| Price | $100.25 | $29.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 119.8K | ★ 590.5K |
| Earning Date | 06-04-2026 | N/A |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.37 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $45.61 | $27.42 |
| 52 Week High | $106.84 | $33.32 |
| Indicator | ODC | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 70.98 | 35.43 |
| Support Level | $70.50 | $27.42 |
| Resistance Level | N/A | $33.32 |
| Average True Range (ATR) | 3.37 | 2.96 |
| MACD | 0.07 | -0.22 |
| Stochastic Oscillator | 56.43 | 39.20 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.